| Indication | For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. |
| Pharmacodynamics | Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor |
| Mechanism of action | Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression. |
| Absorption | Not Available |
| Volume of distribution | |
| Protein binding | 96% |
| Metabolism | Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4 |
| Route of elimination | Dasatinib is extensively metabolized in humans, primarily by the cytochrome P450 enzyme 3A4. Elimination is primarily via the feces. |
| Half life | The overall mean terminal half-life of dasatinib is 3-5 hours. |
| Clearance | Not Available |
| Toxicity | Acute overdose in animals was associated with cardiotoxicity. |
No comments:
Post a Comment